The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...

Grim revelations have surfaced from within the Department of Health and Human Services (HHS), exposing a culture of censorship surrounding critical discussions about the COVID-19 vaccine and its ...

CEO and chairman Albert Bourla told Yahoo Finance Executive Editor Brian Sozzi during Yahoo Finance's annual Invest conference that the $10 billion acquisition of GLP-1 maker Metsera (MTSR) is part of ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

Delaware says COVID-19 vaccines are available at state clinics, regardless of insurance status. But only 2 clinics carried ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

Catch up with recent coverage below. A Broward radiologist working in Palm Beach might have misdiagnosed a scan right before the patient died from a brain hemmorhage. Florida Blue said it notified ...

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided ...

Get the latest stock market update and key takeaways in healthcare, including Pfizer, Amgen, Novo Nordisk results, and obesity drug bidding wars.

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

The More the Merrier, a new original Hallmark movie, features Abbott HeartMates, a program that provides support for people impacted by heart health challenges. The movie is set to premiere during ...

Moderna posted a smaller-than-expected quarterly loss and reduced its annual operating expenses outlook by $700 million on Thursday, helped by lower production costs and a cutback in research and ...